Dogwood Therapeutics, Inc.
DWTX
$4.90
$0.102.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 167.76% | 133.84% | 16.58% | -8.57% | -11.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 194.85% | 124.48% | -8.99% | -37.84% | -47.50% |
| Operating Income | -194.85% | -124.48% | 8.99% | 37.84% | 47.50% |
| Income Before Tax | -329.81% | -133.19% | 8.22% | 38.25% | 48.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -333.55% | -133.18% | 8.22% | 38.25% | 48.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -333.55% | -133.18% | 8.22% | 38.25% | 48.28% |
| EBIT | -194.85% | -124.48% | 8.99% | 37.84% | 47.50% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -168.48% | -57.83% | 25.17% | 57.49% | 70.77% |
| Normalized Basic EPS | -83.91% | -52.29% | 25.17% | 57.49% | 70.77% |
| EPS Diluted | -168.48% | -57.83% | 25.17% | 57.49% | 70.77% |
| Normalized Diluted EPS | -83.91% | -52.29% | 25.17% | 57.49% | 70.77% |
| Average Basic Shares Outstanding | 57.13% | 36.73% | 20.23% | 25.26% | 40.29% |
| Average Diluted Shares Outstanding | 57.13% | 36.73% | 20.23% | 25.26% | 40.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |